This clinical trial is focused on studying a condition known as ulcerative colitis, which is a chronic disease that causes inflammation and sores in the digestive tract, specifically affecting the innermost lining of the large intestine and rectum. The study is investigating a new treatment called Zasocitinib, also known by its code name TAK-279. This medication is taken orally in the form of a capsule. The trial will compare the effects of Zasocitinib with a placebo to determine its effectiveness and safety in treating people with moderately to severely active ulcerative colitis.

The purpose of the study is to evaluate whether Zasocitinib can help achieve clinical remission, which means reducing the symptoms of ulcerative colitis, by the 12th week of treatment. Participants in the study will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The trial will last for a total of 52 weeks, with the main focus on the first 12 weeks to assess the initial response to the treatment.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the effects of the treatment. These assessments will include evaluating symptoms such as stool frequency and rectal bleeding, as well as conducting endoscopic examinations to observe the condition of the colon. The study aims to provide valuable information on the potential benefits of Zasocitinib for individuals suffering from ulcerative colitis, with the hope of improving their quality of life.